Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys

SAN FRANCISCO--(BUSINESS WIRE)--Nov 13, 2025--

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it. Labs measures key markers over time and provides doctor-developed action plans that can power real shifts in health outcomes. With this new, proactive experience, Hims & Hers is making it accessible, affordable, and simple for customers to get and stay healthy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113242066/en/

With rising costs, limited provider availability, and a bias towards one-size-fits-all care, today’s healthcare system is not built to keep people healthy. 70% of medical decisions depend on a lab test. 1 However, access to these tests is often limited or inconvenient, and results can be difficult to interpret – all of which can lead to missed diagnoses or negative health outcomes. As one of the largest consumer healthcare platforms, Hims & Hers is well-positioned to increase access to health information and follow-up care previously reserved for the very wealthy.

“Truly transformational, preventive care has been out of reach for too many people for too long. With Labs, we’re bringing the benefits of data-driven, proactive healthcare to everyone,” said Andrew Dudum, co-founder and CEO at Hims & Hers. “We’re changing the status quo by making it simple to understand and act on results that matter for your long term health."

With Labs, customers can partner with Hims & Hers for insights across areas like heart health, metabolism, hormones, inflammation, and stress for better health. Results are easy to understand and paired with doctor-developed action plans with lifestyle guidance and access to personalized treatment plans, if deemed appropriate by a healthcare provider. Not only can Labs help keep customers healthier, it powers a more intelligent Hims & Hers platform that helps providers make decisions more tailored to the individual. The company expects to expand the offering over time, with plans to introduce at-home testing devices, additional biomarker tests in areas like bone and brain health, and advanced diagnostics that detect chronic and life-threatening conditions.

“Lab results are at the center of decision-making in primary care and we’re making them simpler, more personal and more actionable,” said Dr. Pat Carroll, Chief Medical Officer at Hims & Hers. “Most chronic conditions are entirely preventable, but develop long before symptoms appear. We’re connecting the dots in a fragmented system to make it easier for people to get and stay healthy.”

With two plans available, eligible customers can choose the level of detail that is right for them and affordably get the insights they need to monitor, maintain, and improve their overall health. Base includes one yearly blood draw that captures 50 biomarker tests, across 9 categories, and is available for $199 a year. Advanced includes two yearly blood draws that capture over 120 biomarker tests, across 10 key categories, and is available for $499 a year. Both plans include doctor-developed action plans and access to personalized treatment plans, if deemed appropriate by a healthcare provider. 2

For more information, visit hims.com/labs and forhers.com/labs.

Media Kit

LINK

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Cautionary Note Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding our expectations regarding subscriber growth and customer adoption of the lab testing offering, the timing and market acceptance of any new products or offerings, the pricing of any new products or offerings, our market opportunity, the growth of the lab testing offering, our ability to innovate on or expand the scope of our offering, including with respect to potential devices, tests or diagnostic capabilities, and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, failure of the lab testing offering to perform as expected; limited market acceptance of this offering; inability to achieve expected subscriber growth; failure to realize the revenue we anticipate to generate from this offering; inability to incorporate or introduce devices, tests or diagnostic capabilities compatible with this offering; inability to obtain or maintain regulatory approvals; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; competitive product launches; higher than anticipated launch or marketing costs; shifts in consumer spending or behavior; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of November 13, 2025. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.

We may include statements and information in this communication concerning our industry and the markets in which we operate, including our market opportunity, which are based on information from independent industry organizations and other third-party sources (including industry publications, surveys and forecasts). While we believe these third-party sources to be reliable as of the date of this communication, we have not independently verified any third-party information and such information is inherently imprecise.

 

With Labs, Hims & Hers is creating an accessible, affordable, data-driven future for healthcare.

NEW YORK (AP) — A jury has found that concert giant Live Nation and its Ticketmaster subsidiary had a harmful monopoly over big concert venues, dealing the company a loss in a lawsuit over claims brought by dozens of U.S. states.

A Manhattan federal jury deliberated for four days before reaching its decision Wednesday in the closely watched case, which gave fans the equivalent of a backstage pass to a business that dominates live entertainment in the U.S. and beyond.

At the end of the proceeding, the judge told lawyers on both sides to meet with one another “and the United States” to provide a joint letter proposing a schedule for motions and how the remedies phase of the case would occur. He told them to deliver it by late next week.

Live Nation Entertainment owns, operates, controls booking for or has an equity interest in hundreds of venues. Its subsidiary Ticketmaster is widely considered to be the world’s largest ticket-seller for live events. Its lawyers did not immediately comment as they left the courthouse, but said a statement would be issued shortly.

The verdict could cost Live Nation and Ticketmaster hundreds of millions of dollars, just for the $1.72 per ticket that the jury found Ticketmaster had overcharged consumers in 22 states. The companies could also be assessed penalties. In addition, sanctions could result in court orders that they divest themselves of some entities, including venues such as amphitheaters that they own.

The civil case, initially led by the U.S. federal government, accused Live Nation of using its reach to smother competition — by blocking venues from using multiple ticket sellers, for example.

“It is time to hold them accountable,” Jeffrey Kessler, an attorney for the states, said in a closing argument, calling Live Nation a “monopolistic bully” that drove up prices for ticket buyers.

Live Nation insisted it's not a monopoly, saying that artists, sports teams and venues decide prices and ticketing practices. A company lawyer insisted its size was simply a function of excellence and effort.

“Success is not against the antitrust laws in the United States,” attorney David Marriott said in his summation.

Ticketmaster was established in 1976 and merged with Live Nation in 2010. The company now controls of 86% of the market for concerts and 73% of the overall market when sports events are included, according to Kessler.

Ticketmaster has long drawn ire from fans and some artists. Grunge rock titans Pearl Jam battled the business in the 1990s, even filing an anti-monopoly complaint with the U.S. Department of Justice, which declined to bring a case then.

Decades later, the Justice Department, joined by dozens of states, brought the current lawsuit during Democratic former President Joe Biden's administration. Days into the trial, Republican President Donald Trump's administration announced it was settling its claims against Live Nation.

The deal included a cap on service fees at some amphitheaters, plus some new ticket-selling options for promoters and venues — potentially allowing, but not requiring, them to open doors to Ticketmaster competitors such as SeatGeek or AXS. But the settlement doesn't force Live Nation to split from Ticketmaster.

A handful of the states joined the settlement. But more than 30 pressed ahead with the trial, saying the federal government hadn't gotten enough concessions from Live Nation.

The trial brought Live Nation CEO Michael Rapino to the witness stand, where he was questioned about matters including the company’s Taylor Swift ticket debacle in 2022. Rapino blamed a cyberattack.

The proceedings also aired a Live Nation executive's internal messages declaring some prices “outrageous,” calling customers “so stupid” and boasting that the company “robbing them blind, baby.” The executive, Benjamin Baker, apologetically testified that the messages were “very immature and unacceptable.”

FILE - The Ticketmaster logo is seen along the sideline of the field before an NFL football game, Sept. 15, 2024, in Jacksonville, Fla. (AP Photo/Phelan M. Ebenhack, File)